U.S. equity futures showed a mixed picture on Wednesday as investors digested a recent selloff in technology and semiconductor stocks and awaited fresh corporate cues. By 05:51 ET (09:51 GMT), S&P 500 futures had risen 0.16% to 7,377 points, Nasdaq 100 futures were up 0.37% at 29,771.5 points, and Dow Jones futures had slipped 0.19% to 52,054 points.
Market attention remained concentrated on technology-related sectors, including companies tied to artificial intelligence, semiconductors and data center infrastructure, with traders looking ahead to earnings from memory chipmaker Micron for signals about AI-driven demand.
Notable premarket stock moves
- Absci - Shares rose about 24% after the biotechnology company reported positive interim Phase 1 safety data for ABS-201, its investigational antibody treatment for hair loss. The company said the treatment was well tolerated across all dose cohorts and that no serious adverse events were reported.
- FuelCell Energy - The fuel cell technology provider jumped 16% after announcing a strategic agreement with Fit Energy USA to supply up to 380 megawatts of clean power for data centers. The agreement includes an initial 30 MW deployment that is scheduled to begin later this year.
- Cerebras Systems - The AI chip designer tumbled about 14% after forecasting 2026 adjusted gross margins of 38% to 41%, below the 47% margin it reported in the first quarter. The margin outlook was included in the company’s first earnings report since its initial public offering.
- FedEx - The delivery company fell 7.3% after issuing fiscal 2027 earnings guidance that missed Wall Street expectations. Although FedEx reported fourth-quarter earnings and revenue above estimates, investors reacted to the weaker-than-anticipated profit outlook for the upcoming fiscal year.
- Bilibili - The Chinese video-sharing platform climbed 2.4% after unveiling a new $300 million share repurchase program. The buyback authorization will remain in place for 24 months and follows a period of improving profitability and revenue growth.
Overall, the early-session moves highlighted a split between companies buoyed by clinical trial progress or commercial agreements and those weighed down by conservative margin or earnings guidance. Technology names continued to be monitored closely for quarterly updates and forward-looking statements that could influence sentiment across related sectors.